Is Thyrocare Technologies the Best Stock in Its Sector? A Look at the Numbers
- October 14, 2026
- Posted by: Kunal Singla
- Category: Market
Thyrocare Technologies CMP Rs 499 (14 Oct 2026). Market cap Rs 7,957 Cr. ROE 27.85%. P/E 45.24x versus Industry P/E 61.61x.
Quick Answer
Thyrocare Technologies is one of the names investors compare when screening the Healthcare sector, built on a 27.85% return on equity and a P/E of 45.24x against an Industry P/E of 61.61x. Whether Thyrocare Technologies is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Thyrocare Technologies the best stock in its sector? The stock trades on the NSE at Rs 499 as of 14 October 2026, within its 52-week range of Rs 342.55 to Rs 662.00. Thyrocare Technologies Ltd, headquartered in Navi Mumbai, is a diagnostics company that runs a centralised laboratory model, processing samples collected from across India.
Thyrocare Technologies sits in the Healthcare sector, and its 27.85% ROE and 45.24x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Thyrocare Technologies
Thyrocare Technologies Ltd, headquartered in Navi Mumbai, is a diagnostics company that runs a centralised laboratory model, processing samples collected from across India. Thyroid, wellness and routine blood tests are among its core offerings, and it also pays a dividend yield of 2.80%. Its 15.52x price to book ratio is high, which is worth weighing alongside its returns. The stock trades about 25 percent below its 52-week high and about 46 percent above its 52-week low. At a market capitalisation of Rs 7,957 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Thyrocare Technologies the Best Stock in Its Sector?
Thyrocare Technologies makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 27.85% ROE with a 45.24x P/E against the sector’s 61.61x Industry P/E. Thyrocare’s 45.24x P/E is below the 61.61x Industry P/E, Dr Lal PathLabs at 58.73x and Metropolis Healthcare at 54.79x, while its 27.85% ROE is the highest of the three, ahead of Dr Lal PathLabs at 20.13% and Metropolis Healthcare at 12.56%.
| Metric | Thyrocare Technologies |
|---|---|
| CMP (NSE) | Rs 499.10 |
| 52-Week High / Low | Rs 662.00 / Rs 342.55 |
| Market Cap | Rs 7,957 Cr |
| P/E (TTM) vs Industry P/E | 45.24x vs 61.61x |
| P/B | 15.52 |
| ROE | 27.85% |
| EPS (TTM) | Rs 11.05 |
| Dividend Yield | 2.80% |
| Debt to Equity | 0.09 |
Compare Thyrocare Technologies Against Other Healthcare Sector Stocks
How Thyrocare Technologies Compares Against Its Healthcare Sector Peers
The table below sets Thyrocare Technologies against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Thyrocare Technologies | 7,957 | 45.24 | 27.85% | 0.09 |
| Dr Lal PathLabs | 32,084 | 58.73 | 20.13% | 0.08 |
| Metropolis Healthcare | 11,116 | 54.79 | 12.56% | 0.15 |
| Peer average (2 companies) | – | 56.76 | 16.34% | 0.11 |
Against this peer set, Thyrocare Technologies’s 27.85% ROE is above the 16.34% peer average, and its P/E of 45.24x runs below the peer average of 56.76x. Thyrocare’s 45.24x P/E is below the 61.61x Industry P/E, Dr Lal PathLabs at 58.73x and Metropolis Healthcare at 54.79x, while its 27.85% ROE is the highest of the three, ahead of Dr Lal PathLabs at 20.13% and Metropolis Healthcare at 12.56%.
What Makes Thyrocare Technologies Worth Watching in Healthcare
- Valuation discount: A 45.24x P/E sits below the 61.61x Industry P/E, Dr Lal PathLabs at 58.73x and Metropolis Healthcare at 54.79x.
- Strong returns: A 27.85% ROE is higher than Dr Lal PathLabs at 20.13% and Metropolis Healthcare at 12.56%.
- Leverage: A debt to equity ratio of 0.09 is close to Dr Lal PathLabs at 0.08 and below Metropolis Healthcare at 0.15.
Thyrocare Technologies Valuation: Is It Justified?
Thyrocare’s 45.24x P/E is below the 61.61x Industry P/E, Dr Lal PathLabs at 58.73x and Metropolis Healthcare at 54.79x, while its 27.85% ROE is the highest of the three, ahead of Dr Lal PathLabs at 20.13% and Metropolis Healthcare at 12.56%. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Alkem Laboratories the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Thyrocare Technologies and other Healthcare sector stocks.
How to Track Thyrocare Technologies Before You Invest
Before deciding whether Thyrocare Technologies deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Thyrocare Technologies to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Thyrocare Technologies earns a place in the best stock in its sector conversation on the strength of a 27.85% ROE and a P/E of 45.24x against a 61.61x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Thyrocare Technologies the best stock in its sector?
Ans. Thyrocare Technologies has a 27.85% ROE and trades at 45.24x P/E against a 61.61x Industry P/E, and compares above the peer average ROE of 16.34% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Thyrocare Technologies?
Ans. Thyrocare Technologies was trading at Rs 499.10 on the NSE as of 14 October 2026, within its 52-week range of Rs 342.55 to Rs 662.00.
What sector does Thyrocare Technologies belong to?
Ans. Thyrocare Technologies is classified under the Healthcare sector on Univest.
How does Thyrocare Technologies compare to its sector peers on P/E?
Ans. Thyrocare Technologies’s P/E of 45.24x is below the 56.76x average of the 2 named peers compared in this article.
What is Thyrocare Technologies’s return on equity?
Ans. Thyrocare Technologies reported a return on equity of 27.85%, which is above the 16.34% average of its named peers in this comparison.
Should I invest in Thyrocare Technologies based on its sector position?
Ans. Thyrocare Technologies’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Thyrocare Technologies the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Thyrocare Technologies has a 27.85% ROE and trades at 45.24x P/E against a 61.61x Industry P/E, and compares above the peer average ROE of 16.34% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of Thyrocare Technologies?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Thyrocare Technologies was trading at Rs 499.10 on the NSE as of 14 October 2026, within its 52-week range of Rs 342.55 to Rs 662.00.”}}, {“@type”: “Question”, “name”: “What sector does Thyrocare Technologies belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Thyrocare Technologies is classified under the Healthcare sector on Univest.”}}, {“@type”: “Question”, “name”: “How does Thyrocare Technologies compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Thyrocare Technologies’s P/E of 45.24x is below the 56.76x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is Thyrocare Technologies’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Thyrocare Technologies reported a return on equity of 27.85%, which is above the 16.34% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in Thyrocare Technologies based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Thyrocare Technologies’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}
